Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other
A phase 1/2 trial of JDQ443, Trametinib, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments is a phase 1/2 interventional study registered as NCT07468071 by Novartis Pharmaceuticals, with 40 participants planned, started 2026-06-08 and due to reach its primary completion in 2029-06-11. Interventions recorded: Opnurasib, TNO155, trametinib, cetuximab, tislelizumab. Conditions listed: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares JDQ443, Trametinib, Cetuximab, Novartis.
- TrialStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares TNO155, JDQ443, Tislelizumab, Non-small-cell lung cancer.
- TrialStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Shares JDQ443, Novartis, Non-small-cell lung cancer.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Shares JDQ443, Non-small-cell lung cancer.
- TrialStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonJie Wang
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.